Medtronic, the global leader in medical technology and Samsung today announced a broad-based strategic alliance to accelerate the development of digital health solutions for the millions of people suffering from chronic pain, movement disorders, incontinence, and other conditions who could benefit from neuromodulation therapy.
The alliance will leverage Samsung’s deep understanding of consumer technology and mobility to develop advanced tools, based on the Android operating system, aimed at improving how patients and physicians interact with and receive data from Medtronic’s clinically-proven neuromodulation systems.
People with these conditions, as well as their healthcare providers, need convenient access to mobile technology to better manage their health. Medtronic is developing a range of future solutions that will enhance and help deliver personalized patient care and improve healthcare outcomes.
By integrating neuromodulation therapies with Samsung technology, Medtronic seeks to deliver real-time health data to physicians and patients so they can more effectively manage the therapy, track symptoms and wirelessly monitor data received from Medtronic devices.
In June 2015, Medtronic and Samsung announced a similar collaboration to enable solutions to improve diabetes management for the millions of people at risk and currently living with the disease. The first project focuses on delivering more discreet and convenient access to personal diabetes data by developing mobile applications optimized for Samsung mobile devices that will enable the viewing of insulin pump and continuous glucose monitoring (CGM) sensor information.
